| Shen, Lin |
NCT05167071: HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003, Toripalimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 10/23 | 06/24 | | |
NCT05262491: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor |
|
|
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gastrointestinal Tumor | 08/24 | 08/24 | | |
NCT06134960: NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor |
|
|
| Not yet recruiting | 1 | 12 | RoW | KD-496 | Peking University, KAEDI | Gastric Cancer, Pancreatic Cancer, Solid Tumor | 06/26 | 11/26 | | |
NCT06353152: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1 | 12 | RoW | Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection | Peking University, Gracell Biopharmaceuticals, Inc. | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 11/25 | 11/25 | | |
NCT04121286: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China |
|
|
| Recruiting | 1 | 24 | RoW | JAB-3312 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors | 12/23 | 12/23 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 08/24 | 08/24 | | |
NCT05638828: A Study of RD14-01 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 24 | NA | RD14-01 Cell injection | Shen Lin | Solid Tumor | 12/23 | 12/24 | | |
NCT05374226: A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas |
|
|
| Recruiting | 1 | 172 | RoW | JS019 | Suzhou Kebo Ruijun Biotechnology Co., Ltd | Advanced Solid Tumors or Lymphomas | 12/23 | 03/24 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
NCT06170294: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | TCR-MAGE-A4 T-Cells, MAGE-A4-directed T cell receptor-engineered T Cells | Peking University, Shanghai Ming Ju Biotechnology Co., Ltd. | Advanced Solid Tumor | 12/25 | 12/28 | | |
NCT06197178: A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) |
|
|
| Recruiting | 1 | 42 | RoW | LCAR-G08 cells | Peking University, Nanjing Legend Biotech Co. | Advanced Gastrointestinal Tumors | 11/25 | 03/28 | | |
| Not yet recruiting | 1 | 110 | NA | XKH002 Injection, XKH002 | Suzhou Kanova Biopharmaceutical Co., LTD | Advanced or Metastatic Solid Tumors | 12/25 | 04/26 | | |
NCT05183243: Dose Finding Study of GH21 in Adult Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 68 | RoW | GH21 Capsule | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumor, Pancreatic Cancer, Colorectal Cancer, Head and Neck Tumor, Non-small-cell Lung Cancer | 12/24 | 02/25 | | |
NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
| Recruiting | 1 | 24 | RoW | UCMYM802 Injection | UTC Therapeutics Inc., Peking University Cancer Hospital & Institute | Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer Female | 03/25 | 04/25 | | |
NCT06240546: First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 102 | RoW | LPM6690176, LY01024 | Luye Pharma Group Ltd. | Advanced Solid Tumor | 02/26 | 02/27 | | |
| Active, not recruiting | 1 | 204 | Europe, Japan, US, RoW | M1774, Tuvusertib, Niraparib | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Metastatic or Locally Advanced Unresectable Solid Tumors | 01/25 | 01/25 | | |
NCT04856150: A Study of Q-1802 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 66 | RoW | Q-1802 | QureBio Ltd. | Advanced Solid Tumors | 04/24 | 07/24 | | |
| Recruiting | 1 | 30 | RoW | BL-M05D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Solid Tumors | 05/26 | 05/26 | | |
YMCART9601, NCT05287165: Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms |
|
|
| Recruiting | 1 | 19 | RoW | IM96 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Advanced Solid Tumors, Digestive System Neoplasms, Pancreatic Cancer Resectable, Colorectal (Colon or Rectal) Cancer | 04/24 | 06/24 | | |
NCT05730361: Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors |
|
|
| Not yet recruiting | 1 | 48 | NA | ScTIL injection, ScTIL injection and B lymphocytes adjuvant | Peking University | Digestive System Malignant Solid Tumors | 05/24 | 08/24 | | |
| Not yet recruiting | 1 | 17 | RoW | KH801 | Beijing Kanghong Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 05/26 | 05/30 | | |
NCT06380309: A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE |
|
|
| Recruiting | 1 | 60 | RoW | IDOV-SAFE | Peking University | Advanced Malignant Solid Tumor of Digestive System | 11/25 | 10/27 | | |
NCT05320874: A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. |
|
|
| Not yet recruiting | 1 | 232 | RoW | KM257 Bispecific antibody | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor | 06/24 | 11/26 | | |
NCT05650242: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 177 | RoW | BA1106 | Shandong Boan Biotechnology Co., Ltd | Solid Tumors | 06/24 | 12/24 | | |
NCT05770310: A Phase I Study Of JS015 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 114 | RoW | JS015 | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Advanced Solid Cancer | 06/24 | 07/25 | | |
NCT05933668: Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor |
|
|
| Not yet recruiting | 1 | 11 | RoW | YK0901 cells | Peking University, Yingkai Saiwei（Beijing）Biotechnology Co., Ltd | Advanced Solid Tumor | 07/24 | 07/26 | | |
M108-Ⅰ, NCT04894825: Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China |
|
|
| Recruiting | 1 | 152 | RoW | M108, Chemotherapy, Chemotherapy. | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Advanced Unresectable Solid Tumors | 07/24 | 12/24 | | |
NCT04280341: JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | RC48-ADC in combinaton with JS001 | Peking University, RemeGen Co., Ltd. | HER2-Positive Solid Tumors | 12/24 | 12/24 | | |
| Recruiting | 1 | 78 | Japan, RoW | Pimitespib, TAS-116, Imatinib, Sunitinib | Taiho Pharmaceutical Co., Ltd. | Gastrointestinal Stromal Tumors | 12/25 | 12/25 | | |
| Recruiting | 1 | 50 | RoW | TR128 | Tarapeutics Science Inc. | Advanced Solid Tumor | 08/25 | 12/25 | | |
| Recruiting | 1 | 276 | RoW | SKB410 for injection | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 06/25 | 06/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
NCT05981235: Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors |
|
|
| Recruiting | 1 | 96 | RoW | AZD6422 CLDN18.2 CAR-T product, AZD6422 | Peking University, AstraZeneca | Gastrointestinal Tumors | 06/26 | 11/28 | | |
| Recruiting | N/A | 600 | RoW | FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Targeted Agent, Other Therapy, Other Drugs | Peking University, Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China | Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Gastrointestinal Stromal Tumors, Pancreatic Cancer, Neuroendocrine Tumors, Unknown Primary Cancer, Digestive Cancer | 02/24 | 02/24 | | |
NCT06331923: Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Diabetic Patients |
|
|
| Recruiting | N/A | 10168 | RoW | Continuous glucose monitoring (CGM) device | Beijing Tsinghua Chang Gung Hospital, Peking University International Hospital, Wang Jing Hospital, ZhuHai Hospital, Beijing Hospital, Siyang County Hospital of Traditional Chinese Medicine, Second Hospital of Shanxi Medical University, Henan Provincial Chest Hospital, Fuzhou First Hospital, Pinggu Hospital of Beijing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Mindong Hospital of Ningde, The Fifth Hospital of Xiamen, People's Hospital of Ningxia Hui Autonomous Region, The First People's Hospital of Changzhou, The Fifth hospital of Deyang, Suzhou Municipal Hospital, Tang-Du Hospital, Yiyang Central Hospital, First Affiliated Hospital of Xinjiang Medical University, Peng Ding Shan Shi Zhong Yi Yi Yuan, Yueyang Central Hospital, The First People's Hospital of Lianyungang, Haimen District Traditional Chinese Medicine Hospital, The 910th Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Beijing Tiantan Hospital, Affiliated Hospital of Jiangsu University, Liaocheng People's Hospital, Beijing Chao Yang Hospital, Jilin City Hospital of Chemical Industry, Creen Hospital-465, Wuhan Central Hospital, Air Force Military Medical University, China, Shanghai Tong Ren Hospital, Beijing Anzhen Hospital, Emergency General Hospital, Beijing Tongren Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, The First Affiliated Hospital of Anhui Medical University, Chinese PLA Central Hospital | Comprehensive Complication Index | 10/25 | 12/25 | | |
NCT06443307: Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan |
|
|
| Recruiting | N/A | 933 | RoW | Irinotecan Liposome | Peking University | Colorectal Cancer, Solid Tumor | 07/26 | 08/26 | | |
NCT05649163: Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy |
|
|
| Not yet recruiting | N/A | 306 | RoW | Disitamab Vedotin, RC48 | Shen Lin, RemeGen Co., Ltd. | HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumor | 01/25 | 05/25 | | |
NCT05227378: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer |
|
|
| Not yet recruiting | N/A | 36 | RoW | neoantigen tumor vaccine with or without PD-1/L1 | Shen Lin, NeoCura | Gastric Cancer | 03/25 | 08/25 | | |
CGOG-EV-1001, NCT04993378: Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy |
|
|
| Recruiting | N/A | 40 | RoW | EV-array | Shen Lin | Advanced Gastric Adenocarcinoma, Immunotherapy | 04/21 | 07/21 | | |
NCT04500990: MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study |
|
|
| Recruiting | N/A | 40 | RoW | MRI test | Peking University | Immunotherapy, Digestive System Neoplasm | 07/21 | 07/21 | | |
NCT05697107: Ripretinib in Chinese Patients With Advanced GIST: a Real World Study |
|
|
| Active, not recruiting | N/A | 308 | RoW | Ripretinib Oral Tablet | Peking University, First Affiliated Hospital, Sun Yat-Sen University, Wuhan Union Hospital, China, Sun Yat-sen University, Fudan University, Xiangya Hospital of Central South University, Fujian Medical University Union Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Chongqing Medical University, RenJi Hospital | Gastrointestinal Stromal Tumors | 08/22 | 12/23 | | |
NCT05165602: Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System |
|
|
| Not yet recruiting | N/A | 30 | RoW | | Peking University | HER2 Positive Gastric Cancer | 05/23 | 05/23 | | |
NCT05593419: Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers. |
|
|
| Recruiting | N/A | 300 | RoW | TIIC signature | Peking University | Gastric Cancer Patients Received Immunotherapy | 10/25 | 10/25 | | |
| Kavan, Petr |
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy |
|
|
| Active, not recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe | RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 07/25 | 07/28 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 2/3 | 1912 | Canada, US | Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month | NRG Oncology, Natera, Inc., National Cancer Institute (NCI) | Stage III Colon Cancer | 03/29 | 03/30 | | |
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer |
|
|
| Terminated | 2 | 177 | Europe, Canada, US | Drug GC4711, Placebo | Galera Therapeutics, Inc. | SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer | 11/23 | 11/23 | | |
| Active, not recruiting | 2 | 350 | Europe, Canada, US | 9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar | Actuate Therapeutics Inc. | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 11/24 | 11/25 | | |
| Recruiting | 2 | 720 | Canada | Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib | Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc. | Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors | 01/26 | 01/27 | | |
| Recruiting | 1/2 | 368 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Ning, Liao |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
NCT02389699: Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ |
|
|
| Active, not recruiting | N/A | 74 | RoW | Intraoperative Radiotherapy, Whole breast radiation | Liao Ning | Breast Neoplasms | 06/19 | 06/24 | | |
NCT02389673: Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer |
|
|
| Recruiting | N/A | 222 | RoW | Intraoperative Radiotherapy | Liao Ning | Breast Neoplasms | 06/19 | 06/26 | | |
NCT02389686: Intra-operative Radiotherapy For Breast Cancer Women After NSM |
|
|
| Recruiting | N/A | 110 | RoW | INTRABEAM (Carl Zeiss, Oberkochen, Germany) | Liao Ning | Breast Neoplasms | 10/19 | 10/24 | | |
| Wang, Xiaojia |
NCT05131841: Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC |
|
|
| Recruiting | 4 | 60 | RoW | Cipterbin Combined With Vinorelbine | Zhejiang Cancer Hospital, Proswell Medical Corporation | Metastatic Breast Cancer | 12/22 | 12/22 | | |
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury |
|
|
| Recruiting | 4 | 165 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention | The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation | Cancer Treatment Induced Thrombocytopenia | 06/24 | 08/24 | | |
NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis |
|
|
| Not yet recruiting | 4 | 384 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Breast Cancer Stage IV | 10/25 | 10/27 | | |
NCT05110170: Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® |
|
|
| Completed | 3 | 188 | RoW | LY01005, Goserelin Acetate Sustained-Release Microspheres for Injection, ZOLADEX® 3.6 mg, Goserelin Acetate Implant 3.6 mg | Luye Pharma Group Ltd. | Breast Cancer | 04/22 | 06/22 | | |
NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 3 | 565 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Recruiting | 3 | 270 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 10/23 | 01/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/23 | 12/24 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Recruiting | 3 | 860 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 04/24 | 08/27 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
|
|
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 01/24 | 03/24 | | |
NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
NCT05075512: The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | anlotinib, fulvestrant, AL3818 | Zhejiang Cancer Hospital | Breast Neoplasm Female | 08/23 | 08/26 | | |
NCT05461690: Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency |
|
|
| Not yet recruiting | 2 | 50 | NA | Niraparib, Zejula | Zhejiang Cancer Hospital, Sun Yat-sen University, Hunan Cancer Hospital, Fujian Cancer Hospital, Zhejiang University, Taizhou Hospital of Zhejiang Province | Homologous Recombination Deficiency, Triple Negative Breast Cancer | 12/24 | 06/25 | | |
NCT06092606: A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients |
|
|
| Recruiting | 2 | 90 | RoW | Control group:DH001 placebo, Control group, Trial group: DH001 low-dose group, Trial group: DH001 high-dose group | Monyan Pharmaceutical (Shanghai) Co., Ltd. | Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy, Doxorubicin Adverse Reaction | 01/25 | 01/25 | | |
NCT05110807: A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 38 | RoW | TQB3617 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumors | 10/22 | 12/22 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05861895: A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors |
|
|
| Recruiting | 1 | 84 | US, RoW | HF158K1 /Arm 2 mg/m², Infusion, HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m², HF158K1 /Arm 30 mg/m², HF158K1 /Arm 45 mg/m², HF158K1 /Arm 60 mg/m² | HighField Biopharmaceuticals Corporation | Solid Tumors, Adult | 04/25 | 12/25 | | |
NCT05480189: Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study |
|
|
| Not yet recruiting | N/A | 1000 | NA | Non-intervention | Zhejiang Cancer Hospital | Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis | 08/23 | 03/27 | | |
| Abdalla, Kathia C |
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
|
|
| Recruiting | 4 | 2076 | Europe, Canada, US, RoW | Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance | Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor) | Motor Function, Cognitive Function, Contrast Media | 12/28 | 12/28 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Ahmed, Osama A |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Salvo, Marcelo Adan Garrido |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 74 | Canada, US, RoW | ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine | Jazz Pharmaceuticals | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | 11/25 | 10/26 | | |
| Huang, Xiwen |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
| Kunwei, Shen |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
| Jian, Liu |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
| Wu, Jingna |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
| Perera, Sheron |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT05843188: Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 155 | Canada | Hydroxychloroquine, Irinotecan, Leucovorin, Folinic acid, Fluorouracil, 5-FU, Bevacizumab | University Health Network, Toronto | Metastatic Colorectal Cancer | 04/26 | 10/26 | | |
